share_log

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen-Xbrane进入Cimzia参考Biosimilar，Xcimzane的许可协议
Benzinga Real-time News ·  2022/02/08 10:01

Biogen Inc (NASDAQ:BIIB) and Xbrane Biopharma AB have entered into a license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody, a proposed biosimilar referencing UCB SA's (OTC:UCBJY) Cimzia (certolizumab pegol)

生物遗传公司(纳斯达克：亚投行)和Xbrane Biophma AB已经签订了一项许可协议，开发、生产和商业化Xcimzane，一种临床前单克隆抗体，一种拟议的生物相似参照物联合银行(UCB SA)的(场外交易代码：UCBJY)Cimzia(Certolizumab Pegol)

  • Cimzia's primary indication is for rheumatoid arthritis in adults and axial spondylarthrosis, psoriasis, and Crohn's disease. 
  • In 2020 global sales of Cimzia were €1.8 billion. Under the agreement terms, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane.
  • Biogen will make an upfront payment of $8 million to Xbrane.
  • Xbrane can receive up to $80 million in potential milestone payments and tiered sales-based royalties. 
  • Xbrane will be responsible for completing the preclinical development of Xcimzane, and Biogen will be responsible for all remaining development activities and costs required to achieve Marketing Authorization in all territories, including clinical development.
  • Price Action: BIIB shares traded 1.11% lower at $218.85 on Tuesday.
  • CIMZIA的主要适应症是成人类风湿性关节炎以及轴性脊椎关节病、牛皮癣和克罗恩病。
  • 2020年，Cimzia的全球销售额为18亿欧元。根据协议条款，生物遗传公司将获得Xcimzane的独家全球管理、制造和商业权。
  • Biogen将向Xbrane预付800万美元。
  • Xbrane可以获得高达8000万美元的潜在里程碑付款和基于分级销售的特许权使用费。
  • Xbrane将负责完成Xcimzane的临床前开发，Biogen将负责在所有地区获得营销授权所需的所有剩余开发活动和费用，包括临床开发。
  • 价格行动：周二，亚投行股价下跌1.11%，至218.85美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发